Free Trial

MorphoSys (MOR) Competitors

MorphoSys logo
$18.96 0.00 (0.00%)
As of 07/24/2025

MOR vs. QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, and RGC

Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

MorphoSys vs. Its Competitors

Qiagen (NYSE:QGEN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Qiagen has a net margin of 4.68% compared to MorphoSys' net margin of -226.79%. Qiagen's return on equity of 14.61% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen4.68% 14.61% 8.80%
MorphoSys -226.79%-694.31%-22.55%

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Qiagen presently has a consensus target price of $49.40, indicating a potential downside of 4.62%. Given Qiagen's stronger consensus rating and higher possible upside, equities analysts plainly believe Qiagen is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Qiagen had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Qiagen and 0 mentions for MorphoSys. Qiagen's average media sentiment score of 0.93 beat MorphoSys' score of 0.00 indicating that Qiagen is being referred to more favorably in the media.

Company Overall Sentiment
Qiagen Positive
MorphoSys Neutral

Qiagen has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$1.98B5.82$83.59M$0.40129.49
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

Qiagen has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Qiagen beats MorphoSys on 14 of the 16 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MOR vs. The Competition

MetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.86B$776.92M$5.70B$9.50B
Dividend YieldN/A4.84%4.60%4.01%
P/E Ratio-5.451.4028.1020.05
Price / Sales11.9925.35429.3789.38
Price / CashN/A19.5636.2258.56
Price / Book54.176.798.665.87
Net Income-$205.35M-$4.32M$3.25B$258.55M
7 Day PerformanceN/A1.15%4.22%3.73%
1 Month PerformanceN/A3.76%10.51%11.75%
1 Year Performance2.99%9.52%34.40%18.03%

MorphoSys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
QGEN
QIAGEN
3.7199 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+26.1%$10.75B$1.98B120.495,765Positive News
Analyst Downgrade
Analyst Revision
VTRS
Viatris
2.368 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-20.0%$10.42B$14.74B-2.8132,000
ASND
Ascendis Pharma A/S
3.6186 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+24.6%$10.39B$393.54M-26.751,017Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.8275 of 5 stars
$104.90
flat
$109.00
+3.9%
+375.4%$8.93B$42.28M-52.4530Positive News
BBIO
BridgeBio Pharma
4.6357 of 5 stars
$45.90
-1.3%
$61.50
+34.0%
+73.4%$8.83B$221.90M-13.00400Analyst Downgrade
BPMC
Blueprint Medicines
0.9484 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Positive News
Upcoming Earnings
ROIV
Roivant Sciences
2.649 of 5 stars
$11.48
+0.3%
$16.50
+43.7%
+7.5%$7.78B$29.05M-45.92860News Coverage
Positive News
Insider Trade
LEGN
Legend Biotech
3.6958 of 5 stars
$42.23
+1.5%
$73.33
+73.7%
-26.7%$7.64B$627.24M-71.582,609Positive News
ELAN
Elanco Animal Health
2.6423 of 5 stars
$14.67
-0.8%
$16.00
+9.1%
+16.5%$7.34B$4.44B19.829,000News Coverage
Analyst Forecast
RGC
Regencell Bioscience
0.2069 of 5 stars
$14.40
-0.7%
N/AN/A$7.17BN/A0.0010

Related Companies and Tools


This page (NASDAQ:MOR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners